Molecular basis of juvenile myelomonocytic leukemia

Haematologica

Volumn 95, Issue 2, 2010, Pages 179-182

  De Vries, Andrica C H ^a   Zwaan, C Michael ^a   Van Den Heuvel Eibrink, Marry M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CBL PROTEIN; JANUS KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; STAT PROTEIN;

CANCER SURVIVAL; CHROMOSOME ANALYSIS; EDITORIAL; EPIGENETICS; GENE MUTATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; KARYOTYPE; MONOSOMY 7; NEUROFIBROMATOSIS; NF1 GENE; PROGNOSIS; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TUMOR SUPPRESSOR GENE;

CHILD; GENES, RAS; HUMANS; JANUS KINASES; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MUTATION; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS C-CBL; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 76549094236     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.016865     Document Type: Editorial

References (33)

1. Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol. 1999;106(4):1027-32.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours: Pathology and genetics of Tumours of Haematopoietic and Lymphoid tissues: IARC Press, Lyon, 2001.
3. EWOG-MDS. Clinical Trial Protocol EWOG-MDS 2006. Prospective non-randomized multi-center study for epidemiology and characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML) in childhood. 2007.
4. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res. 2009;33(3):355-62.
5. Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997;89(10):3534-43.
6. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991;77(5):925-9.
7. Emanuel PD. RAS pathway mutations in juvenile myelomonocytic leukemia. Acta Haematol. 2008;119(4):207-11.
8. Kratz CP, Schubbert S, Bollag G, Niemeyer CM, Shannon KM, Zenker M. Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell Cycle. 2006;5(15):1607-11.
9. Syndromes run together in the RAS pathway. Nat Genet. 2006; 38:267.
10. Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood. 1998;92(1):267-72.
11. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12(2):144-8.
12. Flotho C, Steinemann D, Mullighan CG, Neale G, Mayer K, Kratz CP, et al. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene. 2007; 26(39):5816-21.
13. Steinemann D, Arning L, Praulich I, Stuhrmann M, Hasle H, Stary J, et al. Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia (JMML) and neurofibromatosis type 1. Haematologica. 2010;95(1):320-3.
14. Balgobind BV, Van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER, et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood. 2008;11188):4322-8.
15. Flotho C, Valcamonica S, Mach-Pascual S, Schmahl G, Corral L, Ritterbach J, et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999; 13(1):32-7.
16. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34(2):148-50.
17. Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergsträsser E, Emanuel PD, et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood. 2005;106(6):2183-5.
18. Bader-Meunier B, Tchernia G, Miélot F, Fontaine JL, Thomas C, Lyonnet S, et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr. 1997;130(6):885-9.
19. Fukuda M, Horibe K, Miyajima Y, Matsumoto K, Nagashima M. Spontaneous remission of juvenile chronic myelomonocytic leukemia in an infant with Noonan syndrome. J Pediatr Hematol Oncol. 1997;19(2):177-9.
20. Silvio F, Carlo L, Elena B, Nicoletta B, Daniela F, Roberto M. Transient abnormal myelopoiesis in Noonan syndrome. J Pediatr Hematol Oncol. 2002;24(9):763-4.
21. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009;114(9):1859-63.
22. Schmidt MH, Dikic I. The Cbl interactome and its functions. Nat Rev Mol Cell Biol. 2005;6(12):907-18.
23. de Vries AC, Stam RW, Kratz CP, Zenker M, Niemeyer CM, van den Heuvel-Eibrink MM. Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia. Haematologica. 2007;92(11): 1574-5.
24. Kratz CP, Niemeyer CM, Thomas C, Bauhuber S, Matejas V, Bergstrasser E, et al. Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia. Leukemia. 2007;21:1108-9.
25. de Vries AC, Stam RW, Schneider P, Niemeyer CM, van Wering ER, Haas OA, et al. Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia. Haematologica. 2007;92(11):1557-60.
26. Gratias EJ, Liu YL, Meleth S, Castleberry RP, Emanuel PD. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia. Pediatr Blood Cancer. 2005;44(2):142-6.
27. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell. 2008;14(4):335-43.
28. Liu YL, Castleberry RP, Emanuel PD. PTEN deficiency is a common defect in juvenile myelomonocytic leukemia. Leukemia Research. 2009;33(5):671-7.
29. Furlan I, Batz C, Flotho C, Mohr B, Lübbert M, Suttorp M, et al. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009;113(12): 2867-8.
30. Hasegawa D, Manabe A, Kubota T, Kawasaki H, Hirose I, Ohtsuka Y, et al. Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia. Br J Haematol. 2005;128(6):805-12.
31. Johan MF, Bowen DT, Frew ME, Goodeve AC, Reilly JT. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2005;129(1):60-5.
32. Locatelli F, Nollke P, Zecca M, Korthof E, Lanino E, Peters C, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOGMDS/ EBMT trial. Blood. 2005;105(1):410-9.
33. EWOG-MDS. EWOG-MDS RC 06, TCRVbeta repertoire analysis and PNH clones in children with Refractory Cytopenia (RC). An open non-randomised multi-center prospective study. 2006.